PT2846839T - Formulações para a administração de ingredientes ativos - Google Patents

Formulações para a administração de ingredientes ativos

Info

Publication number
PT2846839T
PT2846839T PT13787024T PT13787024T PT2846839T PT 2846839 T PT2846839 T PT 2846839T PT 13787024 T PT13787024 T PT 13787024T PT 13787024 T PT13787024 T PT 13787024T PT 2846839 T PT2846839 T PT 2846839T
Authority
PT
Portugal
Prior art keywords
formulations
delivery
active ingredients
ingredients
active
Prior art date
Application number
PT13787024T
Other languages
English (en)
Inventor
Mamet Julien
Scott C/O Adynxx Inc Harris
George C/O Adynxx Inc Miljanich
Rick C/O Adynxx Inc Orr
William K C/O Adynxx Inc Schmidt
Tony C/O Adynxx Inc Yaksh
David C C/O Adynxx Inc Yeomans
Original Assignee
Adynxx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx Inc filed Critical Adynxx Inc
Publication of PT2846839T publication Critical patent/PT2846839T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT13787024T 2012-05-10 2013-05-09 Formulações para a administração de ingredientes ativos PT2846839T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261645475P 2012-05-10 2012-05-10

Publications (1)

Publication Number Publication Date
PT2846839T true PT2846839T (pt) 2019-05-29

Family

ID=49551465

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13787024T PT2846839T (pt) 2012-05-10 2013-05-09 Formulações para a administração de ingredientes ativos

Country Status (12)

Country Link
US (3) US9700624B2 (pt)
EP (2) EP3511022A1 (pt)
JP (2) JP6251247B2 (pt)
CN (1) CN104487096B (pt)
AU (1) AU2013259402B2 (pt)
BR (1) BR112014027653A2 (pt)
CA (1) CA2872901A1 (pt)
ES (1) ES2724851T3 (pt)
HK (1) HK1208188A1 (pt)
PT (1) PT2846839T (pt)
RU (1) RU2668136C2 (pt)
WO (1) WO2013170086A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141308A2 (en) 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
CN104487096B (zh) * 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
ES2750689T3 (es) 2014-08-15 2020-03-26 Adynxx Inc Señuelos oligonucleotídicos para el tratamiento del dolor
BR112017014090A2 (pt) * 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
EP0580754A1 (en) 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
CA2168245A1 (en) 1993-07-29 1995-02-09 C. Anthony Hunt Polynucleotide decoys that inhibit mhc-ii expression and uses thereof
ES2307293T3 (es) 1993-10-29 2008-11-16 The Brigham And Women's Hospital, Inc. Utilizacion terapeutica de señuelos de elementos en cis in vivo.
DE69534197T2 (de) * 1994-11-17 2006-02-16 Taiho Pharmaceutical Co. Ltd. Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
AU5369396A (en) 1995-03-23 1996-10-08 Research Foundation Of The State University Of New York, The Rest protein and dna
RU2205874C2 (ru) 1995-05-11 2003-06-10 Апплайд Резеч Системз Арс Холдинг Н.В. Нуклеотидная последовательность, способная ингибировать активность il-6, плазмидный вектор для трансфекции в клетки млекопитающих, нуклеотидная последовательность, используемая при терапии, фармацевтическая композиция (варианты)
JP3474879B2 (ja) 1995-05-12 2003-12-08 アンジェスエムジー株式会社 ＮＦ−κＢに起因する疾患の治療および予防剤
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
AU737926B2 (en) 1996-05-20 2001-09-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
US6890909B1 (en) 1997-07-04 2005-05-10 Fujisawa Pharmaceutical Co., Ltd. Brain-protective agent
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
EE200000790A (et) 1998-06-02 2002-04-15 Glaxo Group Limited Geeniteraapia meetod
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6867289B1 (en) 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6008048A (en) 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
AU761136B2 (en) 1998-12-23 2003-05-29 Genentech Inc. Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
US20040192598A1 (en) * 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US20040077573A1 (en) * 2000-11-24 2004-04-22 Hiroki Maruyama Method for regulating the activity of an expression product of a gene transferred into living body
US20020137715A1 (en) 2001-01-03 2002-09-26 Alain Mauviel Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
AU2002241952A1 (en) 2001-01-22 2002-07-30 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
AU2002254132A1 (en) 2001-03-06 2002-09-19 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
JP2005519917A (ja) 2002-02-01 2005-07-07 オメロス コーポレイション 軟骨分解の全身阻害のための組成物および方法
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
TWI231312B (en) 2002-04-26 2005-04-21 Anges Mg Inc Novel dumbbell decoy oligodeoxynucleotides and use thereof
DE10242319A1 (de) 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
AU2003263523A1 (en) * 2002-10-09 2004-05-04 Pfizer Products Inc. Stabilized naked dna compositions
DE10257421A1 (de) 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
KR20120068035A (ko) * 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
EP1644532A4 (en) * 2003-06-30 2007-11-28 Massachusetts Inst Technology EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
WO2005027830A2 (en) 2003-09-12 2005-03-31 Virginia Commonwealth University Chimeric transcription factor decoy oligonucleotides
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060293264A1 (en) 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
JP2008513513A (ja) 2004-09-21 2008-05-01 アネシヴァ， インコーポレイテッド ポリヌクレオチドの送達
DK1799269T3 (en) 2004-09-28 2016-10-03 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases
EP1803811B1 (en) 2004-10-22 2011-05-11 AnGes MG, Inc. Chimeric (double) decoy
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
EP1877556B1 (en) 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
EP3827841B1 (en) 2006-10-09 2024-04-03 Neurofluidics, Inc. Cerebrospinal fluid purification system
AU2008242842B2 (en) 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
WO2008141308A2 (en) * 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
AU2014201462B2 (en) 2007-05-11 2016-09-29 Adynxx, Inc. Gene expression and pain
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
CA2806616C (en) 2010-08-20 2015-08-11 Replicor Inc. Oligonucleotide chelate complexes
WO2012177906A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
DK2734212T3 (da) 2011-07-20 2017-11-06 Hospira Inc Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
BR112014028654A2 (pt) 2012-05-18 2017-10-10 Replicor Inc composições de complexo de quelato de oligonucleotídeo-polipeptídeo e métodos
ES2750689T3 (es) 2014-08-15 2020-03-26 Adynxx Inc Señuelos oligonucleotídicos para el tratamiento del dolor
US20200017853A1 (en) 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
RU2668136C2 (ru) 2018-09-26
BR112014027653A2 (pt) 2017-08-08
WO2013170086A2 (en) 2013-11-14
US10434178B2 (en) 2019-10-08
JP6442027B2 (ja) 2018-12-19
JP2015517501A (ja) 2015-06-22
WO2013170086A3 (en) 2014-03-06
JP2018058866A (ja) 2018-04-12
JP6251247B2 (ja) 2017-12-20
US20150111956A1 (en) 2015-04-23
EP2846839A2 (en) 2015-03-18
US20190374644A1 (en) 2019-12-12
US9700624B2 (en) 2017-07-11
ES2724851T3 (es) 2019-09-16
EP2846839A4 (en) 2016-01-06
CA2872901A1 (en) 2013-11-14
AU2013259402A1 (en) 2014-11-27
EP3511022A1 (en) 2019-07-17
EP2846839B1 (en) 2019-02-20
CN104487096A (zh) 2015-04-01
AU2013259402B2 (en) 2017-12-21
HK1208188A1 (en) 2016-02-26
CN104487096B (zh) 2020-09-15
US20180015165A1 (en) 2018-01-18
RU2014149700A (ru) 2016-07-10

Similar Documents

Publication Publication Date Title
HRP20181855T1 (hr) Lipidi za formulacije namijenjene unosu terapijskog sredstva
IL251647B (en) Oral veterinary preparations for the treatment of parasites containing active factors that act systemically
HK1182010A1 (en) Liquid pharmaceutical composition for the delivery of active ingredients
EP2849770A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS
EP2934482A4 (en) ADMINISTRATIVE FORMULATIONS
PL2841549T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PL2841548T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
ZA201306000B (en) Stable formulation
HK1208188A1 (en) Formulations for the delivery of active ingredients
ZA201306643B (en) Formulation comprising phenylaminopyrimidine derivatives as active agent
PL2908835T3 (pl) Stabilne formulacje
LT2934544T (lt) Farmacinė kompozicija, apimanti ciklezonidą
HK1179534A1 (en) Coated preparation containing azosemide as active ingredient
IL236466B (en) Pharmaceutical composition for the release of active components
PL2908837T3 (pl) Kompozycje do dostarczania leku
GB201110632D0 (en) Drug delivery formulations
PT2704698T (pt) Forma farmacêutica para a libertação controlada de princípios activos
EP2883546A4 (en) NOVEL DIFFERENTIALLY RELEASING PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE INGREDIENTS
HK1209339A1 (en) Pharmaceutical formulations
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
GB201211406D0 (en) Pharmaceutical formulations